- Home
- CR vs PCVX Comparison
CR vs PCVX Comparison
Compare CR & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- PCVX
- Stock Information
- Founded
- CR 1855
- PCVX 2013
- Country
- CR United States
- PCVX United States
- Employees
- CR N/A
- PCVX N/A
- Industry
- CR Metal Fabrications
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- CR Industrials
- PCVX Health Care
- Exchange
- CR Nasdaq
- PCVX Nasdaq
- Market Cap
- CR 10.9B
- PCVX 4.4B
- IPO Year
- CR N/A
- PCVX 2020
- Fundamental
- Price
- CR $186.84
- PCVX $35.76
- Analyst Decision
- CR Strong Buy
- PCVX Strong Buy
- Analyst Count
- CR 4
- PCVX 10
- Target Price
- CR $197.75
- PCVX $136.50
- AVG Volume (30 Days)
- CR 350.5K
- PCVX 1.5M
- Earning Date
- CR 07-28-2025
- PCVX 08-05-2025
- Dividend Yield
- CR 0.50%
- PCVX N/A
- EPS Growth
- CR 54.50
- PCVX N/A
- EPS
- CR 5.76
- PCVX N/A
- Revenue
- CR $2,178,600,000.00
- PCVX N/A
- Revenue This Year
- CR $10.22
- PCVX N/A
- Revenue Next Year
- CR $11.07
- PCVX N/A
- P/E Ratio
- CR $32.17
- PCVX N/A
- Revenue Growth
- CR 17.22
- PCVX N/A
- 52 Week Low
- CR $127.04
- PCVX $27.66
- 52 Week High
- CR $195.00
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- CR 55.46
- PCVX 57.77
- Support Level
- CR $186.53
- PCVX $31.79
- Resistance Level
- CR $195.00
- PCVX $36.89
- Average True Range (ATR)
- CR 4.15
- PCVX 1.51
- MACD
- CR -0.39
- PCVX 0.37
- Stochastic Oscillator
- CR 56.47
- PCVX 77.65
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and electronics, and process flow technologies. Crane generated approximately $2.1 billion in revenue in 2024.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.